Terms: = Ovarian cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Prognosis
10 results:
1. [Expression and significance of immune checkpoint B7-homolog 4 in endometrial cancer].
Zong LJ; Xiang Y; Yu SN; Lu ZH; Chen J; Huang WH
Zhonghua Fu Chan Ke Za Zhi; 2022 Dec; 57(12):921-931. PubMed ID: 36562226
[No Abstract] [Full Text] [Related]
2. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
Hazama Y; Tsujioka T; Kitanaka A; Tohyama K; Shimoya K
PLoS One; 2022; 17(7):e0271245. PubMed ID: 35802681
[TBL] [Abstract] [Full Text] [Related]
3. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
[TBL] [Abstract] [Full Text] [Related]
4. SIRT1 and gynecological malignancies (Review).
Chen J; Chen H; Pan L
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649834
[TBL] [Abstract] [Full Text] [Related]
5. Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: A systematic review and PRISMA-compliant meta-analysis.
Ye Y; Wang JJ; Li SL; Wang SY; Jing FH
Medicine (Baltimore); 2018 Aug; 97(32):e11821. PubMed ID: 30095655
[TBL] [Abstract] [Full Text] [Related]
6. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
[TBL] [Abstract] [Full Text] [Related]
7. The expression of H3K9Ac, H3K14Ac, and H4K20TriMe in epithelial ovarian tumors and the clinical significance.
Zhen L; Gui-lan L; Ping Y; Jin H; Ya-li W
Int J Gynecol Cancer; 2010 Jan; 20(1):82-6. PubMed ID: 20057286
[TBL] [Abstract] [Full Text] [Related]
8. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
Oikonomopoulou K; Li L; Zheng Y; Simon I; Wolfert RL; Valik D; Nekulova M; Simickova M; Frgala T; Diamandis EP
Br J Cancer; 2008 Oct; 99(7):1103-13. PubMed ID: 18766180
[TBL] [Abstract] [Full Text] [Related]
9. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
[TBL] [Abstract] [Full Text] [Related]
10. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract] [Full Text] [Related]